Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331304

Institution ID

3331304

Institution full name and acronym

University of North Carolina at Chapel Hill

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

Assessing the generalizability of all-cause mortality from the MOSAIC trial to older adults diagnosed with stage II and III colon cancer in SEER-Medicare (Generalizability of colon cancer trial results)
Association between glucagon-like peptide 1 receptor agonist (GLP1-RA) and sodium glucose co-transporter 2 inhibitor (SGLT2i) use and COVID-19 outcomes: A national retrospective cohort study
Association between Pioglitazone and Bladder Cancer in a Medicare population
Comparative Effectiveness and Safety of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in Older Adults with Type 2 Diabetes
Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: Impact of Study Design Differences on Comparative Safety Results
Dipeptidyl Peptidase-4 Inhibitors and Risk of Inflammatory Bowel Disease among Patients with Type 2 Diabetes Mellitus
Effect of Cinacalcet Discontinuation on Biochemical Control for Medicare Beneficiaries with Part D Coverage Treated within a Large US Dialysis Provider (20130335)
Effect of Incretin Analogues and Dipeptidyl-peptidase-IV inhibitors on colorectal cancer risk
Effect of Incretin Analogues and Dipeptidyl-peptidase-IV inhibitors on the risk of thyroid cancer
Estimating Oral Anticoagulant Comparative Effectiveness in the Setting of Effect Heterogeneity: Comparing Clinical Trial Transport and Observational Epidemiologic Methods
Incretin-based therapies and Pancreatic Cancer risk in Medicare enrollees – new user protocol
Incretin‐based drugs and Retinopathy risk in Medicare Enrollees
Is Intravenous Bisphosphonate Use Associated with a Higher Risk of a Flare in Inflammatory Bowel Disease Patients? (Bisphosphonates and IBD Flare Risk)
Newer glucose-lowering agents versus thiazolidinediones on risk of incident cirrhosis and clinical decompensation events in patients with diabetes (Second-line GLDs and liver complications)
Prevalence and patterns of medication deintensification following severe hypoglycemia among older adults with diabetes
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT-2i) Use and Risk of Subsequent Amputation
Sodium-glucose cotransporter-2 inhibitor initiation and the short-term risk of hospitalized acute kidney injury (SGLT2 inhibitors and short-term AKI)